Boston Scientific Corporation $BSX Shares Newly Acquired by Financial Solutions Advisory Group Inc.

Financial Solutions Advisory Group Inc. acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 25,293 shares of the medical equipment provider’s stock, valued at approximately $1,123,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. BlackRock Inc. acquired a new position in Boston Scientific during the second quarter valued at approximately $5,534,781,000. Primecap Management Co. CA bought a new position in Boston Scientific in the second quarter valued at approximately $2,156,233,000. Jupiter Topco LLC bought a new position in Boston Scientific in the second quarter valued at approximately $803,357,000. Janus Henderson Group PLC increased its position in shares of Boston Scientific by 31.0% during the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after purchasing an additional 3,907,981 shares during the last quarter. Finally, Amundi increased its position in shares of Boston Scientific by 1.2% during the 2nd quarter. Amundi now owns 14,296,121 shares of the medical equipment provider’s stock worth $610,158,000 after purchasing an additional 173,208 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, CEO Michael Mahoney bought 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Habiger purchased 2,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 189,522 shares of company stock valued at $9,157,810. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Third-quarter revenue increased 1.5% year over year to $5.138 billion, topping the $5.07 billion consensus estimate, while adjusted earnings of $0.73 per share matched expectations. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Robert W. Baird raised its price target from $50 to $51 and maintained an “outperform” rating, while BTIG, UBS and Sanford C. Bernstein retained bullish ratings despite lowering their targets. Analysts revise forecasts after Q3 results
• Positive Sentiment: Management pointed to long-term growth initiatives, including Elite AF trial enrollment and FDA clearances for StoneSmart and SEISMIQ catheter technologies. Recent insider activity also showed purchases rather than sales, offering a modest confidence signal.
• Neutral Sentiment: Boston Scientific expects approximately 4.25% reported full-year 2026 sales growth, but forecast fourth-quarter reported and organic sales declines of 1% to 3%. Boston Scientific cuts view again after cyberattack
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by roughly $150 million and continues to affect operations, customer activity and the recovery timeline.
• Negative Sentiment: Management lowered full-year adjusted EPS guidance to $3.16-$3.18, below investor expectations, and warned that growth could remain broadly flat in 2027 as EP and WATCHMAN weakness, China pricing pressure and product-related challenges persist. BSX Q3 earnings call flags growth challenges
• Negative Sentiment: Analyst sentiment became more cautious: Oppenheimer downgraded BSX to “market perform,” JPMorgan moved to “neutral,” and multiple firms cut price targets, including Wells Fargo to $45 and Needham to $48.

Boston Scientific Trading Up 0.6%

Shares of Boston Scientific stock opened at $42.69 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The business has a fifty day simple moving average of $44.93 and a two-hundred day simple moving average of $57.15. Boston Scientific Corporation has a 1 year low of $39.57 and a 1 year high of $105.65. The company has a market capitalization of $61.86 billion, a price-to-earnings ratio of 18.09, a P/E/G ratio of 1.04 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same period in the previous year, the company earned $0.75 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Research analysts forecast that Boston Scientific Corporation will post 3.18 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Oppenheimer cut Boston Scientific from an “outperform” rating to a “market perform” rating in a research note on Thursday. Royal Bank Of Canada set a $52.00 target price on shares of Boston Scientific in a research note on Thursday. Stifel Nicolaus lowered their target price on shares of Boston Scientific from $60.00 to $55.00 and set a “buy” rating on the stock in a report on Monday. Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 price target (down from $78.00) on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Deutsche Bank Aktiengesellschaft set a $48.00 price target on shares of Boston Scientific in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.87.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.